Dianthus Therapeutics, Inc.
DNTH
$24.33
$0.923.93%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.87% | 102.36% | 120.63% | 51.41% | 8.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.87% | 102.36% | 120.63% | 51.41% | 8.57% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 17.87% | 102.36% | 120.63% | 51.41% | 8.57% |
| SG&A Expenses | 18.29% | 24.22% | 37.64% | 46.47% | 176.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 84.92% | 100.98% | 111.96% | 78.49% | 72.71% |
| Operating Income | -88.94% | -100.90% | -111.45% | -80.58% | -79.04% |
| Income Before Tax | -102.46% | -100.61% | -95.08% | -55.64% | -56.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -102.46% | -100.61% | -95.08% | -55.64% | -56.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -102.46% | -100.61% | -95.08% | -55.64% | -56.89% |
| EBIT | -88.94% | -100.90% | -111.45% | -80.58% | -79.04% |
| EBITDA | -89.01% | -100.99% | -111.55% | -80.61% | -79.05% |
| EPS Basic | 41.27% | 83.75% | 89.75% | 93.10% | 86.58% |
| Normalized Basic EPS | 40.02% | 83.38% | 89.60% | 92.98% | 86.51% |
| EPS Diluted | 41.27% | 83.75% | 89.75% | 93.10% | 86.58% |
| Normalized Diluted EPS | 40.02% | 83.38% | 89.60% | 92.98% | 86.51% |
| Average Basic Shares Outstanding | 79.20% | 207.72% | 530.86% | 1,568.15% | 2,147.23% |
| Average Diluted Shares Outstanding | 79.20% | 207.72% | 530.86% | 1,568.15% | 2,147.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |